Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Core Scientific Inc (CORZ) vs Cassava Sciences Inc (FLNA) Price & Performance

Core Scientific IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Core Scientific Inc vs Cassava Sciences Inc — how do they compare? Core Scientific Inc trades at $20.62 (market cap $6.25B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Core Scientific Inc is far larger — about 130.9× Cassava Sciences Inc's market cap, and Core Scientific Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

CORZFLNA
Market Cap
$6.25B$47.75M
Sector
TechnologyHealth
52-Week High
$29.16$4.64
52-Week Low
$13.55$0.87
Enterprise Value
$8.78B-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Core Scientific Inc

Core Scientific (CORZ) trades at $21.01, down 0.19% on the day, with technical indicators showing a bearish trend despite neutral oscillators. The company reported Q2 2026 revenue growth but missed earnings expectations with a significant net loss of -$1.4 billion for 2026. Recent news highlights a major partnership with AMD for AI infrastructure development, potentially driving future revenue growth through colocation services.

While analyst consensus remains strongly bullish with an 86% buy rating and $35.88 price target, fundamental risks include persistent negative profit margins and substantial cash burn. The AMD partnership offers significant upside potential, but investors must weigh execution risks against the company's current unprofitability and competitive pressures in the data center market.

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Core Scientific Inc

Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.

Read more on CORZ

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA